The objective was to measure the impact of exposure to coxibs and non-steroidal antiinflammatory drugs (NSAID) on morbidity and mortality in older patients with acute myocardial infarction (AMI). A nested case-control study was carried out using an exhaustive population-based cohort of patients aged 66 years and older living in Quebec (Canada) who survived a hospitalization for AMI (ICD-9 410) between 1999 and 2002. The main variables were all-cause and cardiovascular (CV) death, subsequent hospital admission for AMI, and a composite end-point including recurrent AMI or CV death. Conditional logistic regressions were used to estimate the risk of mortality and morbidity. A total of 19,823 patients aged 66 years and older survived hospitalization for AMI in the province of Quebec between 1999 and 2002. After controlling for covariables, the risk of subsequent AMI and the risk of composite end-point were increased by the use of rofecoxib. The risk of subsequent AMI was particularly high for new rofecoxib users (HR 2.47, 95% CI 1.57-3.89). No increased risk was observed for celecoxib users. No increased risk of CV death was observed for patients exposed to coxibs or NSAIDs. Patients newly exposed to NSAIDs were at an increased risk of death (HR 2.22, 95% CI 1.30-3.77) and of composite end-point (HR 2.28, 95% CI 1.35-3.84). Users of rofecoxib and NSAIDs, but not celecoxib, were at an increased risk of recurrent AMI and of composite end-point. Surprisingly, no increased risk of CV death was observed. Further studies are needed to better understand these apparently contradictory results.
Cyclooxygenase-2, non-steroidal antiinflammatory drugs, cardiovascular mortality, acute myocardial infarction.
Alain Vanasse, Department of Family Medicine, Faculty of Medicine, Université de Sherbrooke 3001 12th Avenue North, Sherbrooke (Quebec) J1H 5N4, Canada. E-mail: Alain.Vanasse@USherbrooke.ca
This project was subsidized by
the Network of Centers of Excellence GEOIDE.
The principal investigator was also supported by
the Department of Family Medicine, Université
de Sherbrooke, the Clinical Research Centre,
Sherbrooke University Hospital; and the Fonds de
Recherche en Santé du Québec.
Share this Article
Related Content In Cardiovascular Disease
Foreword: Heart International. 2021;15(1):1
Welcome to the summer 2021 edition of Heart International. This issue contains 9 informative review articles on a range of topics which we hope will be of interest to all cardiovascular practitioners, regardless of subspecialism. We begin with a review by Chu and Gupta, who explore the use of etripamil nasal spray, a novel preparation […]
Medical Therapy for Secondary Prevention of Atherothrombotic Events in Peripheral Artery Disease
Heart International. 2021;15(1):14-19 DOI: https://doi.org/10.17925/HI.2021.15.1.14
Peripheral artery disease (PAD) is a severe manifestation of systemic atherosclerotic disease that commonly refers to lower-extremity arterial involvement. The global burden of PAD is estimated to involve over 200 million patients, with prevalence increasing by 24% over the past decade.1 In contrast to myocardial infarction and stroke, which are declining in the USA, the […]
Dual Antiplatelet Therapy in Patients with High Cardiovascular Risk
Heart International. 2021;15(1):26-36 DOI: https://doi.org/10.17925/HI.2021.15.1.26
Coronary artery disease (CAD) is encountered on a daily basis in the field of medicine. Between 2009 and 2012, the global prevalence of CAD was 154 million, based on data from the Global Burden of Disease study; for the same period in the USA, it was approximately 15.5 million, based on data collected by the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!